Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 13/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335062 | 0.90 | KMT2A (0.48) | CACNA1BEPHX2GAATDP1L3MBTL1 | |
| SCHEMBL2844339 | 0.90 | CACNA1B (0.60) | CACNA1B | |
| SCHEMBL2422335 | 0.90 | CACNA1B (0.60) | CACNA1B | |
| SCHEMBL67714 | 0.88 | CACNA1B (0.58) | CACNA1BEPHX2GAA | |
| SCHEMBL16497704 | 0.87 | CACNA1B (0.61) | CACNA1B | |
| SCHEMBL16497986 | 0.87 | CACNA1B (0.61) | CACNA1B | |
| SCHEMBL16497855 | 0.87 | CACNA1B (0.61) | CACNA1B | |
| SCHEMBL16497791 | 0.82 | CACNA1B (0.51) | CACNA1BALDH1A1 | |
| SCHEMBL16497805 | 0.82 | CACNA1B (0.51) | CACNA1BALDH1A1 | |
| SCHEMBL1334977 | 0.82 | CACNA1B (0.51) | CACNA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885EPHX2 1564/4885GAA 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.